← Back to all signals
RESEARCH PAPER ANALYSIS

Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.

AI interpretation is pending for this paper.

Open original publication →
PMID39827421
JournalJournal of neuro-oncology
Publication Date2025-01-19
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

PURPOSE: To investigate the prognostic significance of contrast enhancement (CE) in grade 2 oligodendroglioma (ODG) and explore its clinical implications. METHODS: Patients diagnosed with isocitrate dehydrogenase (IDH)-mutant, 1p/19q co-deleted ODG between 2009 and 2016 were retrospectively enrolled from a single institution. The presence of CE was identified on preoperative MRIs, and clinical, radiologic, and histopathological data that was extracted. Subgroup analyses were performed to evaluate differences in these factors and prognoses. Cox proportional hazards regression analyses were used to identify prognostic factors. RESULTS: 258 patients with pathologically confirmed WHO grade 2 ODGs were included. The entire cohort was divided into the CE group (n = 133, 51.6%) and the non-CE group (n = 125, 48.4%). Patients with CE on preoperative MRI showed significantly worse progression-free survival (PFS) compared to those without CE (median PFS: 133 months vs. not reached; p < 0.001) and overall survival (OS) (mean OS: 151 months vs. 155 months; median OS: not reached; p = 0.021). Furthermore, CE presence was identified as an independent prognostic factor in the Cox multivariate analysis. Patients within the CE cohort were further categorized into strong and weak CE subgroups based on the pattern of CE. Logistic regression analysis revealed that non-frontal lobe location (OR = 3.287, p = 0.042), higher Ki-67 index (OR = 3.782, p = 0.027), and 1q/19p co-polysomy (OR = 9.658, p = 0.001) were significantly associated with a higher incidence of the strong CE in ODGs. Furthermore, ODG patients in the strong CE subgroup demonstrated the poorest survival outcomes. CONCLUSION: CE on preoperative MRI is a valuable prognostic marker in the grade 2 ODGs, with strong CE indicating the poorest survival outcomes. Further validation through larger cohort studies will help confirm these findings and refine survival stratification in clinical practice.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Pott's Puffy Tumor Mimicking Langerhans Cell Histiocytosis in a Child. Pediatrics international : official journal of the Japan Pediatric Society 28.5 2 A Population-Based Study of Pediatric and Adult Brainstem Glioma: Prognostic Nomograms for Overall and Cancer-Specific Survival. Turkish neurosurgery 62.02 3 Surgical Management of Third Ventricular Colloid Cysts: The Fate of Open Microsurgery. Turkish neurosurgery 63.5 4 Prenatal Ultrasound and MRI Findings in Two Fetuses With Perineal Lipoma. Congenital anomalies 56.0 5 Undiagnosed Undescended Testis in Young Adults in Saudi Arabia: Examination-Based Prevalence, Sociocultural Barriers to Early Care and Public Health Implications. Arab journal of urology 64.5 6 Neuro-ophthalmological disturbances in pediatric posterior fossa tumors: Prevalence, risk factors, and outcomes. Neuro-oncology advances 63.82 7 The oncology and fertility outcomes in patients with ovarian steroid cell tumors: a single center experience. Journal of ovarian research 57.5 8 Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study. The Lancet medical imaging & theranostics 59.01 9 Correction: Clinical characteristics and risk factors of acute cutaneous graft-vs.-host disease following allogeneic hematopoietic stem cell transplantation in pediatric acute myeloid leukemia: a singlecenter retrospective study. Frontiers in pediatrics 55.0 10 Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead. Journal of inflammation research 57.65 11 When Three Diseases Collide: Human Immunodeficiency Virus, Hodgkin Lymphoma, and Tuberculosis in a Young Child. Pediatric pulmonology 28.5 12 Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study. Journal of the Endocrine Society 58.51 13 Early neuroendocrine signatures of polyendocrine metabolic ovarian syndrome risk: Pubertal programming, social brain signals, and novel therapeutic targets. Journal of neuroendocrinology 62.24 14 Obesity in survivors of childhood cancer. Annals of pediatric endocrinology & metabolism 55.06 15 Risk factors for recurrence in pediatric craniopharyngioma: impact of extensive tumor involvement and growth hormone therapy in a multicenter cohort. Annals of pediatric endocrinology & metabolism 63.36 16 Radiological assessment of radon concentration in drinking water from Lagos State University campus, Nigeria. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 58.7 17 Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders. Pediatric research 63.9 18 Reconstructing the cancer journey: The impact of adolescent and young adult (AYA) patient advisory boards on survivor experiences and advocacy. Journal of psychosocial oncology 57.0 19 Safe electrophysiology-guided resection of an epileptogenic non-exophytic hamartoma at the floor of the fourth ventricle in a child. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 56.4 20 Desire for future children and interest in consultation with a fertility specialist among adolescent and young adult (AYA) cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 57.35 21 Trends in Clinicopathologic Characteristics of Pediatric Differentiated Thyroid Carcinoma: A Single-Center Experience from 1995 to 2022. Endocrinology and metabolism (Seoul, Korea) 56.56 22 Modeling Wilms Tumor Development with Multiple Lineage Human Fetal Kidney Organoids Reveals the Cellular Origin and Specific Drivers of Tumorigenesis. Cancer research 48.5 23 Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors. Journal of the National Cancer Institute 65.24 24 Atrophic Papulosis: A Systematic Review of Pediatric Cases. Pediatric dermatology 53.55 25 Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation. Molecular and cellular pediatrics 63.6 26 Abatacept in biologic-refractory juvenile idiopathic arthritis-associated uveitis: a case-based review. Clinical rheumatology 67.44 27 Paediatric biobanking in the era of precision medicine: ethical, regulatory, and scientific challenges from childhood to adulthood. European journal of pediatrics 53.78 28 Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments). Journal of neuro-oncology 63.57 29 Pediatric and Adult Sinonasal Phosphaturic Mesenchymal Tumors: CDKN2A Copy Number Alterations and Their Association with Recurrence. Head and neck pathology 57.5 30 Systematic review of the impact of germline mutations from unrelated bone marrow donors on post-allogeneic transplantation. Expert review of molecular diagnostics 64.09 31 Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis. PloS one 80.82 32 Eosinophilic angiocentric fibrosis in paediatric IgG4-related disease. BMJ case reports 55.2
PATIENT-FRIENDLY SUMMARY

Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic